The San Diego Biotech Survival Index: Local Firms Make Strong Rebound In First Half of 2009

Luke Timmerman9/23/09Leave a CommentFollow @ldtimmerman

Share

Order a Reprint E-mail this Story

• Tweet

(Page 3 of 4)

Hollis-Eden Pharmaceuticals (NASDAQ: HEPH)
Cash on hand: $15.2 million
Previous Xconomy coverage:
“San Diego Biotech Hollis-Eden Terminates CEO”

Illumina (NASDAQ: ILMN)
Cash on hand: $790 million
Previous Xconomy coverage:
“Illumina Sales Miss Expectations“
“Illumina Shows Its Stuff to Wall Street, Stock Still Slides”

Inovio Biomedical (AMEX: INO)
Cash on hand: $8.3 million
Previous Xconomy coverage:
“Inovio, Fuelled by Swine Flu Fear, Reinvents Itself as Developer of Universal Flu Vaccines”

Isis Pharmaceuticals (NASDAQ: ISIS)
Cash on hand: $637.5 million
Previous Xconomy coverage:
“Isis, Genzyme Use Antisense to Go Where Many Drugs Fail, the Brain“
“Genzyme, Isis Cholesterol Drug Reaches Goal in Pivotal Study, Paving the Way to FDA“
“Isis Pharmaceuticals Second Drug Aims to Block Marker of Heart Disease, Inflammation“
“Alnylam, Isis Offspring, Regulus, Keeps Pushing on Biology’s Bleeding Edge”

Life Technologies (NASDAQ: LIFE)
Cash on hand: $582 million
Previous Xconomy coverage:
“From Merger of Invitrogen and Applied Biosystems, Life Technologies Plans to Grow From San Diego Base”

Ligand Pharmaceuticals (NASDAQ: LGND)
Cash on hand: $55.5 million
Previous Xconomy coverage:
“Ligand Gets Neurogen for $11 Million“
“Ligand Cuts Another Deal With GlaxoSmithKline”

To purchase a much expanded version of this report, in PDF format, click the “Add to Cart” button. For $95,* you’ll get an assessment of each company’s financial position at the end of June compared to six months earlier, the projected length of time it can survive on its existing cash reserves, and an analysis of the strategic moves it has made to stay afloat in the current environment. Click here to see a sample entry. *Price is subject to change without notice.

Metabasis Therapeutics (NASDAQ: MBRX)
Cash on hand: $6.6 million
Previous Xconomy coverage:
“Ailing Metabasis Hires Advisory Firm“
“Metabasis Therapeutics Restructures, Cuts 38 From Staff“
“Latest Metabasis Cutbacks Leave Just Seven Employees”

Neurocrine Biosciences (NASDAQ: NBIX)
Cash on hand: $74 million
Previous Xconomy coverage:
“$75M Financing for Neurocrine
“Neurocrine Cuts Half of Workforce”
… Next Page »

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.